Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Neoplasm Metastasis 1Esophageal Neoplasms 1

Interventions

pembrolizumab 185Carboplatin 131Paclitaxel 123Gemcitabine 122Docetaxel 97Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 65Bevacizumab 65Capecitabine 60atezolizumab 55fludarabine 49Fluorouracil 49Azacitidine 49130-nm albumin-bound paclitaxel 43Irinotecan 42venetoclax 41Trastuzumab 41Cetuximab 40Leucovorin 37Ipilimumab 36Erlotinib Hydrochloride 35Oxaliplatin 32Fulvestrant 32Cytarabine 32avelumab 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × MM-111 × Clear all
NCT01774851 2017-06-22

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Merrimack Pharmaceuticals

Phase 2 Terminated
84 enrolled 10 charts
Gastrointestinal

Esophageal Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡